Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

Inclusion Criteria: * Moderate to severe palmar plantar psoriasis based on physician's global assessment (PGA). * Between 18 and 70 years of age * Negative urine pregnancy test at screening and at baseline * Sexually active men and women of child-bearing potential must agree to use a medically accepted form of contraception (birth control) during the exclusionary medicine wash-out period and throughout the study. * Ability to self inject study drug or have a designee who can do so * Capable of understanding and giving written voluntary informed consent Exclusion Criteria: * Previous treatment with Enbrel® (etanercept) or similar drugs * Receipt of investigational drugs or "biologics" within 4 weeks of the screening visit. * Evidence of skin conditions (e.g. eczema) other than psoriasis that would interfere with evaluations of the study medication. * Receipt of any biologic medication within the previous 6 months that resulted in a decreased white blood cell count (cells to help fight infections) * Ultraviolet light treatment (e.g. UVB, PUVA) within one month prior to study drug initiation. * Receipt of immune-suppressing drugs other than Rheumatrex® (methotrexate) or Soriatane® (acetretin) within 4 weeks prior to the first dose of study drug. Medications you would not be allowed to take during this study include for example, Cytoxan® (cyclosporine), Imuran® (azathioprine), or Sulfazine® (sulfasalazine). If you remain on Rheumatrex® (methotrexate) (≤25 mg/week) or Soriatane…